Buprenorphine and HIV primary care: New opportunities for integrated treatment

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Khalsa, Jag ^a   Vocci, Francis ^a   Altice, Frederick ^b   Fiellin, David ^b   Miller, Veronica ^c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DELAVIRDINE; DIAMORPHINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; OPIATE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; DRUG ABUSE; DRUG DEPENDENCE; HEALTH CARE ORGANIZATION; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATED HEALTH CARE SYSTEM; MORBIDITY; MORTALITY; NATIONAL INSTITUTE ON DRUG ABUSE; OPIATE ADDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33845428621     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508179     Document Type: Review

References (15)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO). AIDS epidemic update: 2004. UNAIDS/01.74E-WHO/CS/CSR/NCS 2004. UNAIDS/WHO, 2004.
2. World Health Organization (WHO). Neuroscience of psychoactive substance use and dependence. Geneva: WHO, 2004.
3. Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 National Survey on Drug Use and Health (NSDUH). Office of Applied Studies, NSDUH series H-24, Department of Health and Human Services (DHHS) publication no. SMA 04-3963. Rockville, MD: DHHS, 2004.
4. Miller V, on behalf of the Forum for Collaborative HIV Research Workshop Participants and Steering Committee Members. Buprenorphine and HIV primary care: report of a Forum for Collaborative HIV Research workshop. Clin Infect Dis 2006; 43(Suppl 4):S254-7 (in this supplement).
5. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006; 43(Suppl 4):S173-7 (in this supplement).
6. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis 2006; 43(Suppl 4):S178-83 (in this supplement).
7. Liu C, Weber K, Robison E, Hu Z, Jacobson LP, Gange SJ. Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther 2006; 3:6.
8. Casado A, Consiglio E, Podzamczer D, Badia X. Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients. HIV Clin Trials 2001; 2:477-83.
9. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl 4):S216-223 (in this supplement).
10. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43(Suppl 4):S224-34 (in this supplement).
11. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43(Suppl 4):S235-46 (in this supplement).
12. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006; 43(Suppl 4):S191-6 (in this supplement).
13. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43(Suppl 4):S184-90 (in this supplement).
14. Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006; 43(Suppl 4):S247-53 (in this supplement).
15. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43(Suppl 4):S197-215 (in this supplement).